Study on the Mechanism of the Buqi Tongqiao Formula in Regulating the PI3K/AKT/mTOR Pathway to Intervene in IgA Nephropathy in Rats

Jinjiang Xu; Man Zhang; Qiuye Wu; Xiongbin Gui; Hang Xu

doi:10.54097/4kk71643

Authors

Jinjiang Xu
Man Zhang
Qiuye Wu
Xiongbin Gui
Hang Xu

DOI:

https://doi.org/10.54097/4kk71643

Keywords:

IgA Nephropathy, Buqi Tongqiao Formula, PI3K/AKT/mTOR, Renal Injury

Abstract

Objective: To explore the molecular mechanism by which Buqi Tongqiao Formula (BQTQF) improves renal injury in rats with IgA nephropathy (IgAN) by regulating the PI3K/AKT/mTOR pathway. Methods: The IgAN rat model was established by intragastric administration of BSA, intraperitoneal injection of CCl₄, and combined intravenous injection of LPS. Thirty rats were randomly divided into the blank group, model group, and BQTQF group. After successful model establishment, the rats were administered continuously for 8 weeks, once a day. Renal function was evaluated by determining 24-hour urinary protein, Scr, and BUN levels. Pathological damage of renal tissue in IgAN rats was observed by HE staining. RT-qPCR and Western blot were used to detect the mRNA and protein expression levels of PI3K, AKT, and mTOR in renal tissue of IgAN rats. Results: Compared with the blank group, the levels of 24hUTP, Scr, and BUN in the model group were significantly increased (P<0.01), renal pathological damage was aggravated, and the mRNA transcription levels and protein expression of PI3K, AKT, and mTOR in renal tissue were elevated. After intervention with BQTQF, the renal function of IgAN rats was significantly improved, histopathological damage was alleviated, and the mRNA transcription levels and phosphorylated protein expression of PI3K, AKT, and mTOR were reduced. Conclusion: BQTQF alleviates renal pathological damage and improves renal function in IgAN rats by regulating the PI3K/AKT/mTOR signaling pathway.

Downloads

Download data is not yet available.

References

[1] Floege J, Rauen T, Tang S C W. Current treatment of IgA nephropathy [J]. Semin Immunopathol, 2021, 43(5): 717-728.

[2] Floege J, Bernier-Jean A, Barratt J, et al. Treatment of patients with IgA nephropathy: a call for a new paradigm [J]. Kidney Int, 2025, 107(4): 640-651.

[3] Gesualdo L, Di Leo V, Coppo R. The mucosal immune system and IgA nephropathy [J]. Semin Immunopathol, 2021, 43(5): 657-668.

[4] Alimohammadi M, Kahkesh S, Abbasi A, et al. LncRNAs and IgA nephropathy: underlying molecular pathways and clinical applications [J]. Clin Exp Med, 2025, 25(1): 140.

[5] Cox S N, Sallustio F, Serino G, et al. Altered modulation of WNT-beta-catenin and PI3K/Akt pathways in IgA nephropathy [J]. Kidney Int, 2010, 78(4): 396-407.

[6] Zhang J, Fang Q, Huang Y, et al. CX3CR1(+) Monocytes/Macrophages Promote Regional Immune Injury in Mesangial Proliferative Glomerulonephritis through Crosstalk with Activated Mesangial Cells [J]. Research (Wash D C), 2025, 8: 0716.

[7] Li S, Li J P. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial [J]. Trials, 2020, 21(1): 31.

[8] Peng L F, Feng J R, Wang M G, et al. Mechanism of Buqi Tongqiao Formula on alleviating the inflammatory injury of nasal mucosa in rats with allergic rhinitis by regulating Treg/Th17 balance [J]. China Journal of Traditional Chinese Medicine and Pharmacy, 2022, 37(03): 1648-1651.

[9] Peng L F, Gui X B, Wang M G, et al. Experimental Study on Improving Water Balance of Nasal Mucosa in Rats with Allergic Rhinitis by Buqi Tongqiao Fang [J]. Liaoning Journal of Traditional Chinese Medicine, 2021, 48(05): 172-175+223.

[10] Lu H Y, Zhang Q L, Jiang X Y, et al. Establishment of rat model with IgA nephropathy [J]. Chinese Journal of Misdiagnostics, 2011, 11(06): 1264-1267.

[11] Zhang T B, Hu X Y, Ba Y M. Application of Medicinal Horns and Paired Herbs in the Treatment of IgA Nephropathy Based on the Theory of 'Chronic Disease Invading the Collaterals': Experience of Dr. Ba Yuanming [J]. Journal of Li-shizhen Traditional Chinese Medicine, 2025, 36(12): 2345-2349.

[12] Shen C, Yu Z X, Zhao W J. Exploration of the Pathogenesis, Differentiation and Treatment of IgA Nephropathy Under the Guidance of the Theory of "Ying Wei Qing Yi" Based on Mucosal Immune Mechanism [J]. Journal of Basic Chinese Medicine, 2025, 31(07): 1154-1158.

[13] Chen J F, Gui X B, Wang M G. Therapeutic effect of intragastric administration of Buqi Tongqiao formula on allergic rhinitis in rats and its mechanism [J]. Shandong Medical Journal, 2024, 64(05): 35-39.

[14] Liu T, Zhuang X X, Zheng W J, et al. Integrative multi-omics and network pharmacology reveal the mechanisms of Fangji Huangqi Decoction in treating IgA nephropathy [J]. J Ethnopharmacol, 2025, 337(Pt 3): 118996.

[15] Wang H, Gao L, Zhao C, et al. The role of PI3K/Akt signaling pathway in chronic kidney disease [J]. Int Urol Nephrol, 2024, 56(8): 2623-2633.

[16] Guo N, Wang X, Xu M, et al. PI3K/AKT signaling pathway: Molecular mechanisms and therapeutic potential in depression [J]. Pharmacol Res, 2024, 206: 107300.

[17] Verma K, Jaiswal R, Paliwal S, et al. An insight into PI3k/Akt pathway and associated protein-protein interactions in metabolic syndrome: A recent update [J]. J Cell Biochem, 2023, 124(7): 923-942.

[18] Yu L, Wei J, Liu P. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer [J]. Semin Cancer Biol, 2022, 85: 69-94.

[19] Zhu X, Shen X, Lin B, et al. Liuwei Dihuang Pills Inhibit Podocyte Injury and Alleviate IgA Nephropathy by Directly Altering Mesangial Cell-Derived Exosome Function and Secretion [J]. Front Pharmacol, 2022, 13: 889008.